On “Re‐randomization tests as sensitivity analyses to confirm immunological noninferiority of an investigational vaccine: Case study” by Luca Grassano et al. (2023, Pharmaceutical Statistics)
Pharmaceutical Statistics · 2024
DOI: 10.1002/pst.2363 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Oleksandr Sverdlov und 2 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Hauptthemen laut MEDLINE: Equivalence Trials as Topic. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
- National Institutes of Health, Bethesda, Maryland, USA.
- Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
ORCID-Profile: Oleksandr Sverdlov, Kerstine Carter
Zitieren
APA
Sverdlov, O., Berger, V. W., & Carter, K. (2024). On “Re‐randomization tests as sensitivity analyses to confirm immunological noninferiority of an investigational vaccine: Case study” by Luca Grassano et al. (2023, Pharmaceutical Statistics). Pharmaceutical Statistics. https://doi.org/10.1002/pst.2363
Vancouver
Sverdlov O, Berger VW, Carter K. On “Re‐randomization tests as sensitivity analyses to confirm immunological noninferiority of an investigational vaccine: Case study” by Luca Grassano et al. (2023, Pharmaceutical Statistics). Pharmaceutical Statistics. 2024. doi:10.1002/pst.2363
BibTeX
@article{Sverdlov2024,
author = {Sverdlov, Oleksandr and Berger, Vance W and Carter, Kerstine},
title = {On “Re‐randomization tests as sensitivity analyses to confirm immunological noninferiority of an investigational vaccine: Case study” by Luca Grassano et al. (2023, Pharmaceutical Statistics)},
journal = {Pharmaceutical Statistics},
year = {2024},
doi = {10.1002/pst.2363}
}
EUVIMED